Lilly says Omvoh achieved comprehensive disease control at one year in ulcerative colitis and Crohn's studies

Eli Lilly reported that Omvoh (mirikizumab-mrkz) helped patients with moderately to severely active ulcerative colitis and Crohn's disease achieve multiple simultaneous treatment goals, or comprehensive disease control, at one year.

Detected & updated continuously · Source: Nebula